Form 4: Aardvark Therapeutics Director Reports Conversion of Preferred Stock to Common Stock

Director Jeffrey Chi reports the conversion of Series C Convertible Preferred Stock to Common Stock in connection with Aardvark Therapeutics' IPO.

Summary

• On February 14, 2025, Jeffrey Chi, a director of Aardvark Therapeutics, reported a transaction involving the conversion of Series C Convertible Preferred Stock into Common Stock.
• The conversion occurred automatically on an 8.474-for-1 basis immediately prior to the closing of Aardvark Therapeutics' initial public offering (IPO).
• 1,130,135 shares of Series C Convertible Preferred Stock were converted into 133,364 shares of Common Stock.
• These shares are indirectly held by Vickers Venture Co-investment LLC, which is managed by Vickers Venture Partners (S) Pte. Ltd., whose directors are Dr. Jeffrey Chi and Dr. Finian Tan.
• Dr. Chi and Dr. Tan disclaim beneficial ownership of these securities except to the extent of their proportionate pecuniary interest.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The filing reflects a standard procedure following an IPO, which is generally a positive event for the company. The conversion of preferred stock to common stock simplifies the capital structure.

Positives

• The conversion of preferred stock to common stock typically simplifies the capital structure of a company, which can be viewed positively by investors.
• The IPO itself is a positive event, indicating investor confidence in the company's future prospects.

Future Outlook

The document does not contain specific forward-looking statements beyond the implication of a recently completed IPO.

Management Comments

• Dr. Chi and Dr. Finian Tan disclaim beneficial ownership of the securities held by Vickers Co-investment, except to the extent of their proportionate pecuniary interest.

Industry Context

This filing is a standard part of the IPO process, where preferred stock held by early investors and insiders is converted to common stock, aligning their interests with public shareholders. This is a common practice in the biotechnology industry as companies mature and seek public funding.

Comparison to Industry Standards

• The conversion of preferred stock to common stock upon an IPO is a standard practice across various industries, including biotechnology.
• Similar conversions are seen in filings from companies like Moderna and BioNTech when they went public.
• The 8.474-for-1 conversion ratio is specific to the terms negotiated for the Series C preferred stock of Aardvark Therapeutics and would not be directly comparable to other companies without knowing the specific terms of their preferred stock.

Key Dates

Keywords

Aardvark Therapeutics, Jeffrey Chi, Series C Convertible Preferred Stock, Common Stock, IPO, Conversion, Vickers Venture Co-investment LLC, Director